There are times when a discovery is made and its importance is astounding.
The discovery of biomolecular condensates is such a breakthrough. A revelation so profound, it completely transforms the understanding of cellular function and organization.
We have advanced this new foundational principle of cell biology to shape a daring vision – that the dysregulation of biomolecular condensates explains the root cause of complex diseases and paves the way to novel therapies.
We apply cutting-edge in-silico tools to accelerate how we explore and codify the relationship between condensate biology and human disease, igniting therapeutic possibilities in ways previously unimagined.
We have assembled the most extraordinary talent in condensate science, drug discovery and data science, collaborating across continents and disciplines, and emerging as the world’s leading condensate biotechnology company on a brave path to develop a new generation of medicines.
We are Dewpoint Therapeutics
One evening in the late fall of 2018, Tony Hyman was at his home in Dresden, talking by speakerphone with his new startup co-founder Rick Young back in Cambridge. “Rick and I were discussing how to name the company,” Hyman remembers. “I was walking around the room, and we were coming up with one terrible name after another. ‘Phase Space’ was something I was keen on, and Rick was like, ‘That’s terrible, Tony.’ And then Suzanne came out of the kitchen and said, ‘Why don’t you call it Dewpoint?’”
Hyman and his wife Suzanne Eaton met in California when Hyman was a postdoc, then continued together to Heidelberg, where they both conducted research in cell biology, ultimately moving to Dresden to start the Max Plank Institute of Molecular Cell Biology and Genetics.
In addition to being a leading scientific voice at MPI, Eaton was a Renaissance woman—an accomplished writer, chef, concert pianist, mother, and martial-arts practitioner who was also beloved by the MPI-CBG staff as a thoughtful and infinitely attentive listener and advisor. “She was the best of America in that way,” Hyman says. “She had a real mastery of language and words, a precision – and coming up with our name ‘Dewpoint’ represented that ability to think about language properly.”
With a touch of imagination, our name evokes the moment of phase separation inside cells, when intrinsically disordered proteins and other biomolecules form condensates.
The discovery of biomolecular condensates sparked an entirely new understanding of biology and the way we think about the origin and treatment of diseases. Dewpoint is advancing these learnings to identify new targets and mechanisms of action across multiple biological pathways to develop new therapies.
Dewpoint has developed the ability to tackle the root cause of complex diseases and address previously undruggable targets.
Our ERSAi platform explores and codifies relationships between condensates, human disease and chemistry to accelerate discovery of next generation medicine.
In 2022, we were granted two groundbreaking foundational platform technology patents, cementing our leadership in condensate drug discovery.
Dewpoint is a team of the world’s greatest condensate thought leaders and drug hunters - including our pioneering scientific founders, Tony Hyman and Rick Young, a world-class Scientific Advisory Board led by Nobel Laureate Phil Sharp, and a highly-experienced global leadership team and D. team nearly 150 strong.
Since our founding, we have forged discovery partnerships with leading global pharmaceutical companies across broad therapeutic areas.
Together with our proprietary programs, these collaborations expanded our pipeline and are accelerating our path towards clinical candidates.
With funding from leading tech and biotech investors, we secured a strong financial runway to progress our condensate discovery programs.
In 2022 we strengthened our financial position with a successful Series C raise for $150 million.
Founding investor Polaris Partners led the equity round, joined by Samsara BioCapital, 6 Dimensions Capital, EcoR1 Capital, Alexandria Venture Investments, and Leaps by Bayer.
Round led by ARCH Venture Partners, with participation from new investors Maverick Ventures and Bellco Capital, and existing investors Leaps by Bayer, EcoR1 Capital, Polaris Partners, Samsara BioCapital, and Innovation Endeavors.
Round led by SoftBank Vision Fund 2, along with other new investors General Catalyst, Mubadala Capital, 3E Bioventures, Mirae Asset Capital, and NS Investment. Also joining the round were existing investors Leaps by Bayer, Polaris Partners, Samsara BioCapital, ARCH Venture Partners, EcoR1 Capital, and Maverick Ventures.
Santiago Ramón y Cajal documents membrane-free cellular structures, now known to be condensates
Dewpoint co-founder Tony Hyman and colleagues publish pivotal paper revealing the potential of condensates
Dewpoint founded by pioneering scientists Tony Hyman, Rick Young and Amir Nashat with Nobel Laureate Phil Sharp appointed as SAB chair
US Operations begin
Series A funding, $60M raised
German operations begin
$100M deal with Bayer propels our research in cardiovascular diseases
$350M deal with Merck kicks off research into treatments for HIV
Series B funding, $77M raised
$239 deal with Pfizer starts development of treatments for a rare form of muscular dystrophy
Series C funding, $150M raised
Foundational platform technology patent granted by US Patent Office
“Modulating biomolecular condensates: a novel approach to drug discovery” published in Nature Reviews Drug Discovery
Dewpoint co-founder Tony Hyman awarded 2023 Breakthrough Prize in Life Sciences
Dewpoint opens Frankfurt office
Dewpoint Therapeutics granted second breakthrough condensates platform technology patent by US Patent Office
$55M deal with Novo Nordisk opens collaboration in insulin resistance and diabetic complications with financing potential up to $690 million
Partnership with Chemify to develop a suite of digitally discovered and automatically synthesized novel molecules against condensate targets
Strategic collaboration with Evotec to advance Dewpoint’s oncology programs to “IND” status